Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Financial Statements

  Year Ending Dec 2016 (Update) Year Ending Dec 2015 (Update) Year Ending Dec 2014 (Update) Year Ending Dec 2013 (Update)
Net Income/Starting Line -68.51 -50.79 -45.72 -62.13
Depreciation – Supplemental 26.49 31.87 25.35 22.10
Depreciation/Depletion 26.49 31.87 25.35 22.10
Deferred Taxes -0.10 0.21 1.12 33.25
Unusual Items -2.22 7.16 -- 1.02
Other Non-Cash Items 20.38 17.16 29.98 -3.87
Non-Cash Items 18.16 24.32 29.98 -2.85
Accounts Receivable -9.49 40.25 -21.67 42.56
Inventories -5.80 1.86 4.25 1.57
Prepaid Expenses -0.42 -0.45 -0.72 -0.36
Other Assets 4.85 -8.75 -11.09 -8.99
Accrued Expenses -0.77 -1.33 -0.36 -5.49
Payable/Accrued -4.03 -28.30 5.30 -23.90
Other Liabilities -0.83 -2.16 9.93 2.15
Other Operating Cash Flow 0.00
Changes in Working Capital -16.50 1.13 -14.36 7.55
Cash from Operating Activities -40.46 6.74 -3.63 -2.09
Purchase of Fixed Assets -0.08 -0.22 -0.93 -0.16
Purchase/Acquisition of Intangibles -- --
Capital Expenditures -0.08 -0.22 -0.93 -0.16
Acquisition of Business -- -14.17
Sale/Maturity of Investment -- 3.06 4.09 --
Purchase of Investments -- --
Intangible, Net -- --
Other Investing Cash Flow -0.60 -- -25.00
Other Investing Cash Flow Items, Total -0.60 3.06 -20.91 -14.17
Cash from Investing Activities -0.68 2.84 -21.84 -14.33
Other Financing Cash Flow -4.35 -- -- -4.57
Financing Cash Flow Items -4.35 -- -- -4.57
Cash Dividends Paid - Preferred -0.01
Total Cash Dividends Paid -0.01 -- --
Sale/Issuance of Common 74.54 0.63 0.64 13.11
Repurchase/Retirement of Common -1.40 -0.64 -1.73 -3.16
Common Stock, Net 73.14 -0.01 -1.09 -15.75
Options Exercised 0.20 1.48 1.91 3.58
Warrants Converted -0.33 -- --
Issuance (Retirement) of Stock, Net 73.01 1.47 0.81 -12.17
Long Term Debt Issued -- -- 227.00
Long Term Debt Reduction -- -- -175.00
Long Term Debt, Net -9.01 -- -- 52.00
Issuance (Retirement) of Debt, Net -9.01 -- -- 52.00
Cash from Financing Activities 59.64 1.47 0.81 35.26
Foreign Exchange Effects -0.03 -1.25 -1.71 -2.24
Net Change in Cash 18.48 9.80 -26.36 16.61
Net Cash - Beginning Balance 139.74 129.94 156.31 139.70
Net Cash - Ending Balance 158.22 139.74 129.94 156.31
Cash Interest Paid 3.30 3.30 3.23 1.20
Cash Taxes Paid 0.01 0.34 0.33

In millions of USD (except for per share items)

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.